Divi's Laboratories today said its unit at Choutuppal in Telangana has undergone successful inspection by the US health regulator with no observations.
The company's unit-I at Choutuppal has had an inspection by the United States Food and Drug Administration (USFDA) from May 14-16, 2018, Divi's Labs said in a filing to BSE.
"This was a general cGMP inspection by USFDA. The inspection has been concluded with no 483 observations," it added.
As per USFDA, form 483 observations are issued after conclusion of inspection to notify the company's management of objectionable conditions at its facility.
Shares of Divi's Laboratories today closed at Rs 1,166.15 per scrip on BSE, up 1.50 per cent from the previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)